Cover Image
市場調查報告書

黑色素瘤治療的全球市場:2015年∼2019年

Global Melanoma Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 273264
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
黑色素瘤治療的全球市場:2015年∼2019年 Global Melanoma Therapeutics Market 2015-2019
出版日期: 2015年04月01日 內容資訊: 英文 67 Pages
簡介

全球黑色素瘤治療市場,從2014年到2019年之間,預計以15.40%的年複合成長率擴大。

本報告提供全球黑色素瘤治療市場的狀況和成長預測、供應商的資訊等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 疾病概要

  • 疾病的理解
  • 病因
  • 主要統計
  • 階段
  • 症狀
  • 黑色素瘤的核對表

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 美國的黑色素瘤治療市場
    • 市場規模與預測
  • 英國的黑色素瘤治療市場
    • 市場規模與預測
  • 日本的黑色素瘤治療市場
    • 市場規模與預測
  • 波特的五力分析

第8章 黑色素瘤的開發平台情形

  • 主要的新開發平台分子

第9章 各分類的市場分類

第10章 地理區分

第11章 購買標準

第12章 市場成長因素

第13章 成長因素與其影響

第14章 市場課題

第15章 成長因素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • BMS
    • Merck
    • Roche
    • 其他
  • 其他卓越供應商

第19章 主要供應商分析

  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck

第20章 相關報告

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR5573

About Melanoma

According to Melanoma Research Foundation, melanoma is usually, but not always, a cancer of the skin. Melanoma is defined as a cancer that occurs in melanocytes (cells that make the pigment melanin). Chest and back in men and legs in women are the most likely parts to be affected with melanoma. CM, MM, and OM are the three major categories of melanoma. The exact etiology of melanoma is unknown. According to the American Skin Association, the incidence of melanoma is increasing worldwide. The median age of diagnosis is 59 years and the median age of death due to melanoma is 67 years.

TechNavio's analysts forecast the Global Melanoma Therapeutics market to grow at a CAGR of 15.40 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Melanoma Therapeutics market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of melanoma that are available in the market. The market is divided into four segments: CM, OM, MM, and Others.

TechNavio's report, Global Melanoma Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • BMS
  • Merck
  • Roche

Other Prominent Vendors

  • AB Science
  • Amgen
  • Bayer
  • Celgene
  • Daiichi Sankyo
  • Eisai
  • Galectin Therapeutics
  • GSK
  • Novartis
  • Pfizer
  • Vical
  • ZIOPHARM

Market Driver

  • Increase in Prevalence of Melanoma
  • For a full, detailed list, view our report

Market Challenge

  • Availability of Alternative Treatments
  • For a full, detailed list, view our report

Market Trend

  • Emergence of Combination Therapies
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 3.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Etiology
  • 06.3. Key Statistics
  • 06.4. Stages
  • 06.5. Symptoms
  • 06.6. Checklist of Melanoma

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Melanoma Therapeutics Market in US
    • 07.3.1. Market Size and Forecast
  • 07.4. Melanoma Therapeutics Market in UK
    • 07.4.1. Market Size and Forecast
  • 07.5. Melanoma Therapeutics Market in Japan
    • 07.5.1. Market Size and Forecast
  • 07.6. Five Forces Analysis

08. Melanoma Pipeline Landscape

  • 08.1. Key Emerging Pipeline Molecules

09. Market Segmentation by Category

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2014
    • 18.2.1. BMS
    • 18.2.2. Merck
    • 18.2.3. Roche
    • 18.2.4. Others
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Bristol-Myers Squibb
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Key Product Offerings
    • 19.1.4. Revenue by Geography
    • 19.1.5. Business Strategy
    • 19.1.6. Key Information
    • 19.1.7. SWOT Analysis
  • 19.2. F. Hoffmann-La Roche
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation
    • 19.2.4. Business Segmentation by Revenue 2012 and 2013
    • 19.2.5. Sales by Geography
    • 19.2.6. Business Strategy
    • 19.2.7. Key Information
    • 19.2.8. SWOT Analysis
  • 19.3. Merck
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation by Revenue 2013
    • 19.3.4. Business Segmentation by Revenue 2012 and 2013
    • 19.3.5. Sales by Geography
    • 19.3.6. Business Strategy
    • 19.3.7. Key Developments
    • 19.3.8. SWOT Analysis

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Change of Appearance in Skin Moles: Suspicion of Melanoma
  • Exhibit 3: New Diagnosed Cases of Melanoma 2012
  • Exhibit 4: Stages of Melanoma
  • Exhibit 5: Checklist of Melanoma
  • Exhibit 6: Snapshot of Global Melanoma Therapeutics Market 2014
  • Exhibit 7: Global Melanoma Therapeutics Market 2014-2019 (US$ million)
  • Exhibit 8: Melanoma Therapeutics Market in US 2014-2019 (US$ million)
  • Exhibit 9: Melanoma Therapeutics Market in UK 2014-2019 (US$ million)
  • Exhibit 10: Melanoma Therapeutics Market in Japan 2014-2019 (US$ million)
  • Exhibit 11: Segmentation of Global Melanoma Therapeutics Market by Category
  • Exhibit 12: Segmentation of Global Melanoma Therapeutics Market by Category
  • Exhibit 13: Segmentation of Global Melanoma Therapeutics Market by Geography 2014
  • Exhibit 14: Major Drivers of Global Melanoma Therapeutics Market
  • Exhibit 15: Major Challenges in Global Melanoma Therapeutics Market
  • Exhibit 16: Major Trends in Global Melanoma Therapeutics Market
  • Exhibit 17: BMS: Global Revenue 2009-2012 (US$ million)
  • Exhibit 18: BMS: Revenue of Yervoy in US 2011-2014 (US$ million)
  • Exhibit 19: Merck: YoY Revenue 2010-2013 (US$ billion)
  • Exhibit 20: Roche: Pharmaceutical Sales by Therapeutic Area 2013
  • Exhibit 21: Segmentation of Global Melanoma Therapeutics Market by Vendor 2014
  • Exhibit 22: Bristol-Myers Squibb: Key Product Offerings (Based on Therapeutic Areas)
  • Exhibit 23: Bristol-Myers Squibb: Revenue by Geographical Segmentation 2013
  • Exhibit 24: Business Segmentation of Roche 2013
  • Exhibit 25: Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 26: Roche: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 27: Roche: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 28: Merck: Business Segmentation by Revenue 2013
  • Exhibit 29: Merck: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 30: Merck: Sales by Geography 2013
Back to Top